Non-Pharmacological Management of Neurocardiogenic Syncope  by Abe, Haruhiko et al.
Non-Pharmacological Management
of Neurocardiogenic Syncope
Haruhiko Abe MD FACC1, Ritsuko Kohno MD1, Masataka Sumiyoshi MD2,
Yasushi Oginosawa MD1, Hiroko Takemasa MD1, Takuo Tsurugi MD1,
Toshihisa Nagatomo MD1, Yutaka Otsuji MD FACC1
1The Second Department of Internal Medicine, University of Occupational and Environmental Health,
Kitakyushu, Japan
2Department of Cardiology, Juntendo University Shizuoka Hospital, Shizuoka, Japan
Neurocardiogenic syncope is a common disorder. It is diagnosed by obtaining a detailed
history and performing a head-up tilt test, with or without drug provocation. Several studies
have been performed pertaining to its management. However, no treatment, whether
pharmacological or non-pharmacological, except for counterpressure maneuvers and daily
orthostatic tilt training, has been proven eﬀective. Randomized studies of therapies for
neurocardiogenic syncope are needed.
(J Arrhythmia 2007; 23: 21–24)
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Introduction
Neurocardiogenic syncope, also known as vaso-
vagal or neurally mediated syncope, is the most
common cause of loss of consciousness.1) It is
typically triggered by environmental, physical or
mental stress, with an estimated life-time prevalence
of 35%,1–3) and is diagnosed by head-up tilt test-
ing.4,5) A wide variety of treatments for recurrent
neurocardiogenic syncope has been proposed, in-
cluding beta-adrenergic blockade,4–6) disopyra-
mide,7) and cardiac pacing,8) though none is evi-
dence-based.9,10) Therefore, the choices have been
mostly empiric, on the basis of mechanisms com-
monly believed to cause neurocardiogenic fainting.
However, these therapeutic interventions often fail to
prevent recurrences of syncope. Widely accepted
measures not conﬁrmed to be eﬀective include
explanations of the underlying mechanisms, patient
education, reassurance emphasizing the generally
benign nature of the disorder, recognition of pre-
monitory manifestations, and avoidance of triggers.
Volume expansion by means of increased water and
salt intake or medications is sometimes advised.9–11)
Recently, home orthostatic self-training has been
found highly eﬀective in preventing recurrences of
ordinary, drug-refractory neurocardiogenic syncope,
as well as of the malignant form (deﬁned as >5 sec
asystole during syncope) of the disorder.12–17) How-
ever, the mechanisms of home orthostatic self-
training have not been clariﬁed with respect to its
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preventive eﬃcacy during follow-up. Furthermore,
the time spent by patients must be minimized in
order for home orthostatic self-training to be a useful
and accepted therapeutic option.
Pathophysiology and Pharmacological Thera-
pies
The exact mechanism of neurocardiogenic syn-
cope induced by head-up tilt testing is not clearly
understood.18) Blood pooling in the lower limbs
during head-up tilt testing appears to initiate a
sequence of events that may lead to profound arterial
vasodilation and hypotension in susceptible individ-
uals. This downward displacement of the intravas-
cular volume causes a fall in cardiac output that
activates the arterial baroreceptor reﬂexes, resulting
in reﬂex sympathetic stimulation. The sympatheti-
cally-mediated increase in contractility of a preload-
reduced left ventricular cavity is believed to activate
unmyelinated vagal C-ﬁbers by the ventricular
mechanoreceptors. Stimulation of these receptors
produces a large aﬀerent signal to the brain stem
and inhibits the outﬂow of sympathetic activity.19)
Morillo et al., in 1993,7) observed a decrease in
susceptibility to tilt-induced syncope in patients who
underwent multiple head-up tilt tests to evaluate both
their reproducibility and their therapeutic eﬀects. A
reconditioning of the baroreceptor or mechanore-
ceptor response was suggested to be responsible for
the therapeutic eﬀects. In normal subjects, during
peripheral venous pooling, a compensatory cardio-
pulmonary baroreceptor reﬂex-mediated sympathetic
activity is appropriately activated. In patients prone
to neurocardiogenic syncope these compensatory
mechanisms are followed by a paradoxical sympa-
thetic withdrawal.
These proposed mechanisms of neurocardiogenic
syncope have been the basis for the use of beta-
adrenergic blockade to inhibit the activation of
ventricular mechanoreceptors.4,6) However, in a
recent double-blind, randomized, placebo-controlled
study, atenolol was no more eﬀective than placebo
in tilt-positive syncopal patients.20) Disopyramide,
which inhibits the positive inotropic activity of the
heart and the eﬀerent parasympathetic outﬂow, was
expected to prevent neurocardiogenic syncope. As in
the case of atenolol, however, disopyramide was
ineﬀective, compared to placebo, in the prevention
of tilt-induced neurocardiogenic syncope.7) In a ran-
domized, crossover trial of oral propranolol versus
disopyramide performed by our group, propranolol
prevented tilt-induced syncope in 6 (32%) and
disopyramide in 5 (26%) of 19 patients, a statisti-
cally non-signiﬁcant diﬀerence.21) Tilt-induced syn-
cope was prevented by either propranolol or dis-
opyramide alone in only 9 (47%) patients, while in
10 patients syncope continued to be inducible by
head-up tilt testing. Thus, in that randomized trial,
oral propranolol and disopyramide, when adminis-
tered alone, were both relatively and similarly
ineﬀective in the prevention of tilt-induced neuro-
cardiogenic syncope. These observations are consis-
tent with those made in previous studies,7,20) which
were observational, open-label, underpowered, or of
short duration and, ultimately, provided conﬂicting
evidence regarding the eﬃcacy of beta-adrenergic
blockers in the prevention of neurocardiogenic syn-
cope. However, the latest report from the double-
blind, placebo-controlled Prevention of Syncope
Trial (POST) provided strong evidence that meto-
prolol, compared to placebo, did not prevent neuro-
cardiogenic syncope.22) Therefore, there is currently
no reliable pharmacological therapy for the preven-
tion of neurocardiogenic syncope.
Non-Pharmacological Therapies
1. Physical counterpressure maneuvers
In absence of eﬀective drug therapy, eﬀorts have
been made to develop non-pharmacologic treat-
ments, including patient education and life-style
modiﬁcations. Physical counterpressure maneuvers
(PCM), including leg crossing, muscle tensing or
isometric arm counterpressure maneuvers, have been
shown to raise the blood pressure and control or
abort syncopal episodes under laboratory conditions.
In a multicenter, randomized clinical trial, which
included 223 vasovagal syncopal patients, 170
patients were randomly assigned to standardized
conventional therapy, and 106 patients received
conventional therapy plus training in PCM.23) The
median yearly syncope burden during follow-up was
signiﬁcantly lower in the group trained in PCM than
in the control group. During a mean follow-up of 14
months, 50.9% of patients assigned to conventional
treatment and 31.6% of patients assigned to PCM
had recurrent syncope. The authors concluded that
PCM is a risk-free, eﬀective, and low–cost inter-
vention, which should be used as ﬁrst-line treatment
for patients with neurocardiogenic syncope and
recognizable prodromes.
2. Cardiac pacing
Permanent pacing was introduced in the 1990s
for the treatment of drug refractory neurocardio-
genic syncope, particularly of the cardio-inhibitory
type.24–26) However, neither single nor dual chamber
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pacing at rates between 60 and 70 bpm prevented
syncope,24) because the vasodepressor component
was not eliminated at these pacing rates. In the late
1990s, reports were published of a decrease in rates
of neurally mediated episodes of syncope by over-
drive dual chamber pacing at 100 to 110 bpm, com-
pared to non-paced patients with standard thera-
py.27–29) However, in more recent trials, this was
shown to be attributable to a placebo eﬀect of
pacemaker implants.30,31) Thus, as in the case of drug
therapy, the eﬀectiveness of pacing for neurocardio-
genic syncope has not been conﬁrmed.
3. Home orthostatic self-training
Recent studies have found tilt training to be highly
eﬀective in the prevention of recurrent, refractory,
ordinary or malignant neurocardiogenic syn-
cope.12–17) Ector et al. ﬁrst described, in 1998, the
continuation of a repetitive tilt-training program,
consisting of one or two 30-min sessions daily, in 13
patients with neurocardiogenic syncope diagnosed
with head-up tilt testing, who remained free of
recurrences over a mean follow-up of 7.2 months.12)
They attributed the eﬀects of tilt training to the
repetitive and prolonged exposure of the cardiovas-
cular system to gravitational stress, which might
have a similar therapeutic eﬀect in patients present-
ing with orthostatic intolerance. More recently, Di
Girolamo et al. reported the results of a controlled
study of a tilt-training program consisting of two 40-
min sessions daily for about 18 months in adoles-
cents.13) In that study, syncope was re-induced by
tilt-testing in a single out of 24 patients (4.2%) after
one month of tilt training, in contrast, to 18 out of 23
control patients (73.9%). In addition, over a mean
follow-up of 18:2 5:3 months, none of the 24 tilt-
trained patients (0%) versus 13 of 23 control patients
(56.5%) had spontaneous recurrences of syncope.
These diﬀerences in recurrences of both tilt-induced
and spontaneous syncope between the two study
groups were statistically highly signiﬁcant (both p <
0:0001). We reported a case of malignant neuro-
cardiogenic syncope successfully treated with a tilt-
training program consisting of 1 session of 30min
daily for one year.14)
We examined the eﬃcacy of home orthostatic
self-training in the long-term prevention of neuro-
cardiogenic syncope in patients randomly assigned
to twice daily, versus once daily, versus once every
other day training programs.32) Over follow-ups of
over 6 months, no spontaneous episode of syncope
was observed among the patients assigned to the
twice or once daily training programs. Likewise, no
spontaneous episode of syncope occurred in the once
every other day training group as long as the patients
continued training. However, approximately 50%
of the patients in that group quit the training, and
syncope and presyncope recurred. Therefore, we
recommend that home orthostatic self-training be
performed once daily. The mechanisms behind the
eﬃcacy of this training therapy for neurally medi-
ated syncope have not been entirely clariﬁed.33) In
addition, no randomized, placebo-controlled study
of training therapy for the prevention of neurally
mediated syncope has been performed.
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